Tempus AI, Inc. (TEM)
NASDAQ: TEM · Real-Time Price · USD
89.87
-4.60 (-4.87%)
At close: Oct 14, 2025, 4:00 PM EDT
91.29
+1.42 (1.58%)
After-hours: Oct 14, 2025, 7:59 PM EDT
Tempus AI Employees
Tempus AI had 2,400 employees as of December 31, 2024. The number of employees increased by 100 or 4.35% compared to the previous year.
Employees
2,400
Change (1Y)
100
Growth (1Y)
4.35%
Revenue / Employee
$396,659
Profits / Employee
-$83,223
Market Cap
15.61B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2,400 | 100 | 4.35% |
| Dec 31, 2023 | 2,300 | 348 | 17.83% |
| Dec 31, 2022 | 1,952 | 385 | 24.57% |
| Dec 31, 2021 | 1,567 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TEM News
- 5 days ago - Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy - Business Wire
- 5 days ago - Tempus AI's $100 Breakout — Billionaire Cliff Asness Reaps 60% Windfall - Benzinga
- 13 days ago - Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density - Business Wire
- 22 days ago - Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device - Business Wire
- 4 weeks ago - Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease - PRNewsWire
- 4 weeks ago - Tempus AI stock is cheap as Murrey Math Lines points to more gains - Invezz
- 4 weeks ago - Tempus AI: Is TEM Stock A 10x Growth Story? - Forbes
- 4 weeks ago - Tempus AI Gains FDA Clearance For Updated Pixel To Boost Accuracy And Efficiency In Cardiac Imaging - Benzinga